Oxeia sets investor webinar as concussion drug funding round nears close

Oxeia Biopharmaceuticals will host an investor webinar Sept. 17 featuring CEO Michael Wyand, board member and former NFL quarterback Alex Smith, and co-founder Vishal Bansal as its crowdfunding round on StartEngine approaches a Sept. 24 close. The company is pitching OXE103 as a potential first FDA-approved concussion treatment, backed by early clinical results and a regulatory path it says is already partway cleared.

Why it matters: - Oxeia Biopharmaceuticals is trying to advance OXE103 toward what could become the first FDA-approved drug for concussion. - The company says the program could reach a large market with no approved medicine now available for persistent concussion symptoms. - The funding round closes Sept. 24, giving the company a short window to draw investor interest ahead of the next clinical and regulatory steps.

What happened: - Oxeia will host a live investor webinar on Sept. 17, 2026, from 2:00 p.m. to 2:45 p.m. EDT. - The event will feature CEO Dr. Michael Wyand, board member and former NFL quarterback Alex Smith, and co-founder and trauma surgeon Dr. Vishal Bansal. - Oxeia’s public Regulation Crowdfunding offering on StartEngine closes at 11:59 p.m. PT on Sept. 24, 2026. - Investors can register for the webinar and review the offering before it closes.

The details: - OXE103 is a synthetic form of ghrelin, a naturally occurring hormone. - In a clinical study at the University of Kansas Medical Center, 85% of patients treated with OXE103 responded, compared with 33% receiving standard care alone. - The results were published in the peer-reviewed journal Neurotrauma Reports. - The study was registered as NCT04558346. - Oxeia licensed a completed development package from Daiichi Sankyo that covers nine studies and more than 300 patients. - The company says the FDA confirmed no additional preclinical or safety studies are required before its next trial begins. - Oxeia estimates that development shortcut removed five to seven years and as much as $200 million from the timeline. - The next trial is designed for 160 to 180 patients at 10 to 14 clinical sites and will be randomized and placebo-controlled. - Oxeia says it is working with the FDA on a way to measure whether the drug works, with Laurie Burke, a former FDA associate director for study endpoints and label development, leading that effort. - No FDA-accepted measurement standard exists today for concussion, the company says. - The company cites a peer-reviewed analysis of 311 biopharmaceutical acquisitions in the U.S. and Europe that found the most common acquisition point was after a therapy showed patient response but before final-stage development costs were fully absorbed. - Oxeia says that stage accounted for 33% of transactions in the dataset. - Oxeia says its leadership team has helped build biotechnology companies that sold for about $9 billion combined.

Between the lines: - Alex Smith’s role gives the company a high-profile concussion advocate with firsthand experience from a long NFL career. - The webinar appears aimed at framing OXE103 as a de-risked biotech story, with prior human safety data, a licensing package, and an FDA path already in place. - Oxeia is also trying to signal that the biggest value inflection may come before final approval, not after. - Smith said he joined the board because he wants better outcomes for people affected by concussion and traumatic brain injury. - Smith said helmets and rule changes matter, but do not treat the injury. - Wyand said no FDA-accepted way exists to measure whether a concussion drug works and that the agency has cleared Oxeia to proceed.

What's next: - Oxeia plans to use the Sept. 17 webinar to explain the science behind OXE103, the patient data, the FDA discussion, and the design of the next trial. - The company will also take live questions from attendees during the event. - Oxeia’s next milestone is the larger randomized trial it says will test the therapy’s ability to show efficacy in concussion patients.

The bottom line: - Oxeia is betting that early clinical signal, existing safety data, and a clearer FDA path can help it raise money and move faster toward a potential first-in-class concussion treatment.